Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia

Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm with poor clinical outcome, despite the great progress in treatment in recent years. The selective Bcl-2 inhibitor venetoclax (ABT-199) in combination therapy has been approved for the treatment of newly diagnosed AML patients who are...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kai, Yang, Qianying, Zha, Jie, Deng, Manman, Zhou, Yong, Fu, Guofeng, Bi, Silei, Feng, Liying, Xu-Monette, Zijun Y., Chen, Xiao Lei, Fu, Guo, Dai, Yun, Young, Ken H., Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501858/
https://www.ncbi.nlm.nih.gov/pubmed/32948748
http://dx.doi.org/10.1038/s41419-020-02972-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501858/
https://www.ncbi.nlm.nih.gov/pubmed/32948748
http://dx.doi.org/10.1038/s41419-020-02972-2

Ejemplares similares